O-0026 * FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP
O-0026 * FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search